The Expanding Field of Polycythemia Vera Therapies in 2025

a adăugat un sunet Health

2025-11-09 11:15:13

The polycythemia vera treatment landscape is evolving as patent expirations, high drug costs, and new therapies reshape the market. JAKAFI (ruxolitinib) has long been the leading option for patients resistant or intolerant to hydroxyurea. However, generic competition may not appear as soon as expected, potentially delaying cost relief for patients and healthcare systems. The persistent...

0 Commentarii 0 Distribuiri 75 Views 0 previzualizare